Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
Altimmune (ALT) Stock Price & Analysis
2,599 Followers
ALT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.09 - $14.84
Previous Close$7.37
Volume1.55M
Average Volume (3M)4.34M
Market Cap
$551.62M
Enterprise Value$324.73M
Total Cash (Recent Filing)$197.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-4.6
Beta0.59
Next Earnings
Aug 08, 2024EPS Estimate
-$0.36Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding70,902,191
10 Day Avg. Volume2,961,791
30 Day Avg. Volume4,341,243
Standard Deviation0.56
R-Squared0.00037
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)2.64
Price to Sales (P/S)14122.95
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue762.29
Enterprise Value/Gross Profit762.29
Enterprise Value/Ebitda-3.67
Forecast
1Y Price Target
$23.20Price Target Upside198.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Altimmune News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressScheduled End-of-Phase 2 meeting with the FDA could help crystallize ALT's differentiated value proposition in the obesity program.
Drug EfficacyNew analyses in a late-breaker poster show liver fat reductions with pemvidutide were associated with improvement in inflammatory markers, and NAFLD patients with suspected fibrosis saw clinically meaningful improvement in ELF scores.
Financial StabilityAltimmune has a significant cash runway into the first half of 2026, ensuring financial stability beyond key data releases.
Bears Say
Drug Development SetbacksThe discontinuation of HepTcell, a T cell immunotherapy for hepatitis B, due to insufficient response in Phase 2 trials may negatively impact the company's research pipeline and investor confidence.
Drug Tolerance And SafetyLimited safety data from the NASH trial indicates survodutide appears to be harder to tolerate than pemvidutide, potentially affecting patient adherence and treatment success.
Market CompetitionThe emergence of other effective weight loss therapies could pose additional risk to the company's ability to find a strategic partner for pemvidutide, pressuring its market positioning and revenue potential.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.09 and its highest was $14.84 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is Aug 08, 2024 which is in 86 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on May 09, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.03.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -$0.36.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 70,902,190 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went up 7.821%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Ardsley Advisory Partners. It holds Altimmune Inc’s shares valued at 4M.
---
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.20 (198.20% Upside)
$23.20 (198.20% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 98%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 706.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.79%
12-Months-Change
Fundamentals
Return on Equity
-54.46%
Trailing 12-Months
Asset Growth
0.68%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
ALT Earnings Call
Q1 2024
0:00 / 0:00
---
ALT Stock 12 Month Forecast
Average Price Target
$23.20
▲(198.20% Upside)
Technical Analysis
Best Analysts Covering ALT
1 Year
1 Year Success Rate
14/34 ratings generated profit
1 Year Average Return
+5.97%
reiterated a buy rating 5 days ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +5.97% per trade.
---